Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 5/20 | 0.62 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.62 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.62 |
| ▸ | CDK2 | P24941 | 6/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.55 |
| ▸ | CDK1 | P06493 | 5/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
| ▸ | CDK7 | P50613 | 1/20 | 0.55 |
| ▸ | CCNH | P51946 | 1/20 | 0.55 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 5/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506765 | 0.88 | FLT3 (0.62) | IGF1REGFRKCNH2FLT3MKNK1 | |
| SCHEMBL4513560 | 0.88 | FLT3 (0.75) | IGF1REGFRKCNH2FLT3MKNK1 | |
| SCHEMBL4508214 | 0.86 | FLT3 (0.57) | IGF1REGFRKCNH2FLT3MKNK1 | |
| SCHEMBL4511280 | 0.84 | FLT3 (0.60) | IGF1REGFRKCNH2FLT3MKNK1 | |
| SCHEMBL3042306 | 0.84 | FLT3 (0.78) | IGF1REGFRKCNH2FLT3MKNK1 | |
| SCHEMBL4507729 | 0.83 | FLT3 (0.59) | IGF1REGFRKCNH2FLT3MKNK1 | |
| SCHEMBL4509715 | 0.83 | FLT3 (0.59) | IGF1REGFRKCNH2FLT3MKNK1 | |
| SCHEMBL4518389 | 0.83 | FLT3 (0.59) | IGF1REGFRKCNH2FLT3MKNK1 | |
| SCHEMBL30998031 | 0.83 | EGFR (0.72) | IGF1REGFRKCNH2FLT3MKNK1 | |
| SCHEMBL14719022 | 0.83 | EGFR (0.74) | IGF1REGFRKCNH2FLT3MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | claimed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | IGF1R 408/4885EGFR 598/4885KCNH2 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.